Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.52 |
| ▸ | GRK2 | P25098 | 11/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228076 | 0.85 | NR1H2 (0.60) | ROCK2GRK2NR1H2NR1H3 | |
| SCHEMBL2221104 | 0.82 | NR1H2 (0.41) | ROCK2GRK2NR1H2NR1H3 | |
| SCHEMBL2227534 | 0.82 | RET (0.57) | ROCK2GRK2NR1H2NR1H3 | |
| SCHEMBL5444694 | 0.81 | SMN1; SMN2 (0.54) | ROCK2GRK2NR1H2NR1H3KDM4E | |
| SCHEMBL4789632 | 0.77 | ROCK2 (0.56) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| SCHEMBL14289634 | 0.77 | ROCK2 (0.64) | ROCK2GRK2 | |
| Bromide SCHEMBL4788732 | 0.76 | ROCK2 (0.55) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL4789635 | 0.76 | ROCK2 (0.55) | ROCK2GRK2PDE10ANR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL5118063 | 0.75 | ROCK2 (0.62) | ROCK2GRK2 | |
| SCHEMBL7910285 | 0.75 | ROCK2 (0.56) | ROCK2GRK2PDE10ANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | ROCK2 4471/4885GRK2 2142/4885PDE10A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.